Cardiff Oncology Management

Management criteria checks 3/4

Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 3.92 years. total yearly compensation is $1.55M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth €80.04K. The average tenure of the management team and the board of directors is 2.3 years and 9.7 years respectively.

Key information

Mark Erlander

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	38.4%
CEO tenure	4yrs
CEO ownership	0.05%
Management average tenure	2.3yrs
Board average tenure	9.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Erlander's remuneration changed compared to Cardiff Oncology's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$2m	US$594k	-US$41m
Sep 30 2023	n/a	n/a	-US$41m
Jun 30 2023	n/a	n/a	-US$40m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$2m	US$571k	-US$39m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$4m	US$533k	-US$28m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$1m	US$445k	-US$23m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	US$853k	US$399k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$909k	US$387k	-US$19m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$1m	US$374k	-US$25m

Compensation vs Market: Mark's total compensation ($USD1.55M) is above average for companies of similar size in the German market ($USD695.40K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Erlander (63 yo)

4yrs

Tenure

US$1,547,772

Compensation

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Erlander	CEO & Director	4yrs	US$1.55m	0.055% $ 80.0k
James Levine	Chief Financial Officer	2.8yrs	US$917.72k	0.13% $ 196.2k
Fairooz Kabbinavar	Chief Medical Officer	1.3yrs	US$1.26m	no data
Tod Smeal	Chief Scientific Officer?	2.3yrs	US$4.17m	0% $ 0
Elizabeth Anderson	VP of Finance & Administration	8.8yrs	no data	no data
Brigitte Lindsay	Senior Vice President of Finance	1.3yrs	no data	no data
Charles Monahan	Senior VP of Regulatory Affairs	2.3yrs	no data	no data

2.3yrs

Average Tenure

60.5yo

Average Age

Experienced Management: XE7C's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Erlander	CEO & Director	3.9yrs	US$1.55m	0.055% $ 80.0k
Charles Cantor	Member of Scientific Advisory Board	no data	no data	no data
Gary Pace	Independent Director	4.1yrs	US$114.43k	1.56% $ 2.3m
K. Hirth	Member of Scientific Advisory Board	9.8yrs	no data	no data
Paul Billings	Member of Scientific Advisory Board	11.5yrs	US$35.85k	no data
Rodney Markin	Independent Chairman of the Board	10.3yrs	US$154.43k	0.069% $ 101.6k
Carlo Croce	Member of Scientific Advisory Board	no data	no data	no data
Riccardo Dalla-Favera	Member of Scientific Advisory Board	14.1yrs	no data	no data
Lale White	Independent Director	4.1yrs	US$116.43k	0.27% $ 400.0k
Alberto Bardelli	Member of Scientific Advisory Board	9.7yrs	no data	no data
Renee Tannenbaum	Independent Director	2.9yrs	US$110.43k	0.022% $ 32.7k
Brunangelo Falini	Member of Scientific Advisory Board	14.1yrs	no data	no data

9.7yrs

Average Tenure

71yo

Average Age

Experienced Board: XE7C's board of directors are considered experienced (9.7 years average tenure).

Cardiff Oncology Management

Management criteria checks 3/4

Key information

Recent management updates

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Independent Director recently bought €173k worth of stock

Recent updates

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.25 loss in 1Q 2023)

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Full year 2023 earnings released: US$0.93 loss per share (vs US$0.89 loss in FY 2022)

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released: US$0.22 loss per share (vs US$0.20 loss in 3Q 2022)

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.24 loss in 2Q 2022)

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$0.89 loss per share (vs US$0.72 loss in FY 2021)

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 3Q 2021)

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.17 loss in 2Q 2021)

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

First quarter 2022 earnings released: EPS: US$0 (vs US$0.14 loss in 1Q 2021)

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Independent Director recently bought €173k worth of stock

Chief Financial Officer recently bought €164k worth of stock

Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.51 loss in 2Q 2020)

Independent Director Gary Jacob has left the company

Independent Director Thomas Adams has left the company

Cardiff Oncology, Inc. Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.41 loss in 1Q 2020)

Independent Director recently bought €86k worth of stock

Full year 2020 earnings released: US$1.08 loss per share (vs US$2.80 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.05

Cardiff Oncology, Inc. Updates Data from Its Phase 2 Metastatic Castrate-Resistant Prostate Cancer Trial Were Featured in A Virtual Oral Poster Presentation At the American Society of Clinical Oncology Genitourinary Cancers Symposium

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

New 90-day low: €10.10

Cardiff Oncology, Inc. Developing New Treatment Options for Cancer Patients in Indications with the Greatest Medical Need

Cardiff Oncology Presents Data That Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from Its Expanded Access Program

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology, Inc. Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

New 90-day high: €14.00

New 90-day high: €13.60

Cardiff Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $87.75 million.

New 90-day high: €6.95

Cardiff Oncology, Inc. Presents Data At ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer

New 90-day high - €6.05

First half earnings released

New 90-day high - €4.54

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age